Reference number : 276-2016-2017-Q4-00171, amendment number : , agreement type : C, recipient legal name : Appili Therapeutics Inc.|Appili Therapeutics Inc., recipient country : CA, recipient province : NS, recipient city : Halifax|Halifax, recipient postal code : B3H 0A8, program name english : Atlantic Innovation Fund (AIF) - II, program name french : Fonds d'innovation de l'Atlantique (FIA) - II, program purpose english : nan, program purpose french : nan, agreement title english : 207583, agreement title french : 207583, agreement number : 207583, agreement value : 2803148.0, agreement start date : 2017-03-20, agreement end date : 2018-12-31, description english : Develop a liquid oral suspension for metronidazole, description french : Mettre au point une suspenion orale liquide pour le métronidazole, expected results english : nan, expected results french : nan, additional information english : The assistance type is Conditionally Repayable Contribution., additional information french : Le type d'aide est Contribution à remboursement conditionnel., owner organization : acoa-apeca, owner organization title : Atlantic Canada Opportunities Agency | Agence de promotion économique du Canada atlantique